SEATTLE, WASHINGTON -- (Marketwire) -- 02/15/13 -- VentriPoint Diagnostics (TSX VENTURE: VPT)(OTCQX: VPTDF) is pleased to announce that Dr. Florence Sheehan, VentriPoint's Chief Science Officer (CSO) and a Founder has been asked to give a lecture at the 6th World Congress on Paediatric Cardiology & Cardiac Surgery on Monday, February 18th entitled "Knowledge-Based Reconstruction: The Theory".
"It is wonderful that Dr. Sheehan is receiving the acknowledgment of the international pediatric cardiology community for her decades of hard work to create and validate knowledge-based reconstruction as an rapid and accurate way to analyze the right heart," cheered Dr. George Adams, CEO of VentriPoint.
The group from Manchester Heart Centre in the UK will also present a paper at the World Congress based on their recent research using the VMS entitled "Initial Experience with a Novel Echo-based Magnetic Tracking System for Reconstruction of Right Ventricular Volumes and Function in Adults with Congenital Heart Disease".
The VMS is approved for clinical use in TOF, dextro-transposition of the great arteries (d-TGA) and PAH patients in Canada and Europe and is for investigational use only in the United States.
About the 6th World Congress on Paediatric Cardiology & Cardiac Surgery
The World Congress is held every four years and is the major international scientific event for our global paediatric cardio-community and an opportunity to highlight and review four years of research and technological developments in basic sciences, clinical research and therapeutic interventions. A major theme for this 6th Congress is new imaging modalities which have greatly enhanced the diagnostic power, enabled dramatic new interventions and assisted and guided a great number of surgical innovations. The deployment of these latest tools in the determination of ventricular size and function, and in the analysis of valve performance in rheumatic disease are two focal points for this Congress.
About VentriPoint Diagnostics Ltd.
VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. VMS is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease in children and adults and pulmonary arterial Hypertension are the first applications in a suite of applications for all major heart diseases including cardiovascular disease and heart failure - a multi-billion dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of its VMS tool and the company is pursuing the US-FDA marketing clearance through the 510(k) process.
FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release
VentriPoint Diagnostics Ltd.
Dr. George Adams
(206) 283-0221, ext. 401